Staff Profile Pages

ARTemis: A randomised trial of bevacizumab with neoadjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer-Primary endpoint, pathological complete response (pCR).

Authors: Earl, H.M., Hickish, T. et al.

Journal: JOURNAL OF CLINICAL ONCOLOGY

Volume: 32

Issue: 15

eISSN: 1527-7755

ISSN: 0732-183X

DOI: 10.1200/jco.2014.32.15_suppl.1014

Source: Web of Science (Lite)

ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer: primary endpoint – pathological complete response (pCR).

Authors: Hickish, Hickish, T. et al.

Conference: NCRI Cancer Conference in the Clinical Trials Showcase

Dates: 2-5 November 2014

Source: Manual

Preferred by: Tamas Hickish